Free Trial
NYSE:SENS

Senseonics (SENS) Stock Price, News & Analysis

Senseonics logo
$0.31 -0.04 (-10.92%)
(As of 03:16 PM ET)

About Senseonics Stock (NYSE:SENS)

Key Stats

Today's Range
$0.31
$0.35
50-Day Range
$0.32
$0.44
52-Week Range
$0.31
$0.75
Volume
8.03 million shs
Average Volume
2.78 million shs
Market Capitalization
$168.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00
Consensus Rating
Buy

Company Overview

Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
34th Percentile Overall Score

SENS MarketRank™: 

Senseonics scored higher than 34% of companies evaluated by MarketBeat, and ranked 779th out of 974 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Senseonics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Senseonics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Senseonics' stock forecast and price target.
  • Earnings Growth

    Earnings for Senseonics are expected to grow in the coming year, from ($0.13) to ($0.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Senseonics is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Senseonics is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Senseonics has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for SENS.
  • Dividend Yield

    Senseonics does not currently pay a dividend.

  • Dividend Growth

    Senseonics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for SENS.
  • News Sentiment

    Senseonics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Senseonics this week, compared to 1 article on an average week.
  • Search Interest

    Only 6 people have searched for SENS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Senseonics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Senseonics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Senseonics is held by insiders.

  • Percentage Held by Institutions

    Only 12.36% of the stock of Senseonics is held by institutions.

  • Read more about Senseonics' insider trading history.
Receive SENS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senseonics and its competitors with MarketBeat's FREE daily newsletter.

SENS Stock News Headlines

Senseonics narrows FY24 revenue view to 422M from $22M-$24M, consensus $22.18M
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results
Senseonics Q3 2024 Earnings Preview
See More Headlines

SENS Stock Analysis - Frequently Asked Questions

Senseonics' stock was trading at $0.5701 at the beginning of the year. Since then, SENS shares have decreased by 44.0% and is now trading at $0.3190.
View the best growth stocks for 2024 here
.

Senseonics Holdings, Inc. (NYSE:SENS) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.03). The business had revenue of $4.87 million for the quarter, compared to analysts' expectations of $4.86 million. Senseonics had a negative trailing twelve-month return on equity of 299.69% and a negative net margin of 335.15%.

Senseonics (SENS) raised $45 million in an initial public offering (IPO) on Friday, March 18th 2016. The company issued 15,800,000 shares at $2.85 per share. Leerink Partners, Canaccord Genuity and Raymond James acted as the underwriters for the IPO and BTIG was co-manager.

Top institutional shareholders of Senseonics include Symmetry Partners LLC (0.09%) and GSA Capital Partners LLP (0.06%). Insiders that own company stock include Mukul Jain, Douglas A Roeder, Sharon Larkin, Francine Kaufman, Edward Fiorentino, Anthony R Raab, Nick B Tressler, Timothy T Goodnow and Mirasol Panlilio.
View institutional ownership trends
.

Shares of SENS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Senseonics investors own include Zomedica (ZOM), American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/08/2024
Today
11/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Process control instruments
Sub-Industry
Measuring And Control Equipment
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+465.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-60,390,000.00
Net Margins
-335.15%
Pretax Margin
-335.11%

Debt

Sales & Book Value

Annual Sales
$24.04 million
Book Value
$0.07 per share

Miscellaneous

Free Float
514,687,000
Market Cap
$189.38 million
Optionable
N/A
Beta
0.79
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NYSE:SENS) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners